You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 22, 2025

CLINICAL TRIALS PROFILE FOR SEPTRA DS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Septra Ds

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000655 ↗ A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Completed Glaxo Wellcome Phase 2 1969-12-31 To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.
NCT00000655 ↗ A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Septra Ds

Condition Name

Condition Name for Septra Ds
Intervention Trials
Urinary Tract Infection 5
Abscess 3
Cystic Fibrosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Septra Ds
Intervention Trials
Infections 8
Infection 8
Communicable Diseases 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Septra Ds

Trials by Country

Trials by Country for Septra Ds
Location Trials
United States 53
Canada 7
Belgium 3
Germany 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Septra Ds
Location Trials
Texas 6
Ohio 4
New York 4
Missouri 4
Washington 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Septra Ds

Clinical Trial Phase

Clinical Trial Phase for Septra Ds
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Septra Ds
Clinical Trial Phase Trials
Completed 14
Recruiting 5
Unknown status 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Septra Ds

Sponsor Name

Sponsor Name for Septra Ds
Sponsor Trials
National Cancer Institute (NCI) 4
University of Washington 3
Wilford Hall Medical Center 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Septra Ds
Sponsor Trials
Other 41
NIH 9
U.S. Fed 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

SEPTRA DS: Clinical Trials, Market Analysis, and Projections

Introduction

SEPTRA DS, a combination of trimethoprim and sulfamethoxazole, is a widely used antibacterial drug. Here, we will delve into recent clinical trials, market analysis, and projections for this medication.

Clinical Trials Update

Recent Studies on SEPTRA DS

One of the notable recent studies involving SEPTRA DS is the phase 3 double-blind, placebo-controlled trial examining its efficacy in patients with idiopathic pulmonary fibrosis (IPF). This study, published in JAMA, found that co-trimoxazole (the active ingredients in SEPTRA DS) did not improve composite clinical outcomes among patients with moderate or severe IPF compared to the placebo group[1].

Methodology and Outcomes

The trial involved 342 patients randomized across 39 sites, with a follow-up period ranging from 12 to 42 months. The primary outcome was hospitalization-free survival, and secondary outcomes included lung function, dyspnea scores, and quality of life. The results showed no significant difference between the co-trimoxazole and placebo groups in terms of hospitalization-free survival or other clinical outcomes[1].

Adherence and Safety

The study also reported on adherence and safety. The mean adherence was high in both groups, with 81.4% in the co-trimoxazole group and 85.5% in the placebo group. However, dose reduction was more common in the co-trimoxazole group (19% vs 9% in the placebo group), indicating potential side effects or tolerability issues[1].

Market Analysis

Current Market Status

SEPTRA DS is widely available and has been on the market since 1976. However, its market status can vary by region. For example, in Canada, SEPTRA DS Tablets were cancelled post-market as of 2003, although this does not reflect the global market situation[5].

Indications and Usage

SEPTRA DS is indicated for the treatment of various infections, including urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis, travelers’ diarrhea, shigellosis, and Pneumocystis jirovecii pneumonia. It is effective against a broad range of bacteria, including aerobic gram-positive and gram-negative bacteria[2][4].

Competitive Landscape

The antibacterial market is highly competitive, with numerous other antibiotics available for similar indications. SEPTRA DS competes with other combination antibiotics and single-agent antimicrobials. Its unique mechanism of action, which involves inhibiting two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria, is a key differentiator[2].

Market Projections

Demand and Usage Trends

The demand for SEPTRA DS is expected to remain stable due to its broad spectrum of activity and established use in various clinical settings. However, the rise of antibiotic resistance and the development of new antimicrobial agents could impact its market share.

Regional Variations

Market projections vary by region. In areas where antibiotic resistance is a significant concern, there may be a shift towards newer, more targeted antimicrobials. In contrast, regions with limited access to newer drugs may continue to rely on established medications like SEPTRA DS.

Economic Factors

The cost-effectiveness of SEPTRA DS is a critical factor in its market projection. While it is generally less expensive than some newer antibiotics, its use must be balanced against the risk of developing drug-resistant bacteria. Cost minimization analyses and formulary reviews often influence its inclusion in treatment guidelines[3].

Challenges and Opportunities

Antibiotic Resistance

One of the significant challenges facing SEPTRA DS is the increasing prevalence of antibiotic-resistant bacteria. This necessitates careful use to maintain its effectiveness and prevent the development of resistance[2][4].

New Indications and Formulations

There is an opportunity for SEPTRA DS to be explored for new indications or in combination with other therapies. For example, its use in prophylaxis against Pneumocystis jirovecii pneumonia in immunocompromised patients remains a vital application[2].

Patient and Physician Perspectives

Adherence and Tolerability

Patient adherence and tolerability are crucial for the success of any medication. The high adherence rates in clinical trials suggest that SEPTRA DS is generally well-tolerated, although dose reductions and side effects need to be monitored[1].

Clinical Effectiveness

Physicians often choose SEPTRA DS for its broad-spectrum activity and established efficacy. However, the lack of significant clinical advantage in certain conditions, such as IPF, may influence prescribing decisions[1].

Regulatory Considerations

Approval and Monitoring

SEPTRA DS has been approved for various indications and is subject to ongoing regulatory monitoring. Ensuring compliance with guidelines to reduce the development of drug-resistant bacteria is a key regulatory focus[2][4].

Key Takeaways

  • SEPTRA DS did not show significant clinical benefit in patients with IPF in recent clinical trials.
  • The drug remains widely used for various bacterial infections due to its broad-spectrum activity.
  • Market projections are influenced by antibiotic resistance, regional healthcare policies, and economic factors.
  • Ongoing monitoring and adherence to guidelines are essential to maintain its effectiveness.

Frequently Asked Questions (FAQs)

What are the common indications for SEPTRA DS?

SEPTRA DS is commonly used to treat urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis, travelers’ diarrhea, shigellosis, and Pneumocystis jirovecii pneumonia[2][4].

How does SEPTRA DS work?

SEPTRA DS works by inhibiting two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria through the combination of trimethoprim and sulfamethoxazole[2].

What are the potential side effects of SEPTRA DS?

Potential side effects include skin rash, fever, leukopenia, and elevated liver enzymes, particularly in AIDS patients. Hyperkalemia can also occur, especially at high doses[2][4].

Can SEPTRA DS be used in patients with a history of intolerance?

A history of mild intolerance to SEPTRA DS in AIDS patients does not predict intolerance to subsequent secondary prophylaxis, but any sign of adverse reaction should prompt re-evaluation of therapy[4].

How does antibiotic resistance impact the use of SEPTRA DS?

Antibiotic resistance is a significant concern, and SEPTRA DS should only be used to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria to maintain its effectiveness and prevent resistance[2][4].

Sources:

  1. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Hospitalization-Free Survival Among Patients With Moderate or Severe Idiopathic Pulmonary Fibrosis: The ECLSIP Randomized Clinical Trial. JAMA, 2020.
  2. SEPTRA DS TABLET. FDA Label, 2020.
  3. Uniform Formulary Review Process Under 10 U.S.C. § 1074g. Health.mil, 2010.
  4. DS (Double Strength) Tablets - (trimethoprim and sulfamethoxazole). Pfizer Labeling, 2020.
  5. Product information - Canada.ca. Health Canada, 2003.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.